# US 10,479,836 B2 · Method for treating pulmonary hypertension with interleukin-5 receptor antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,479,836 B2
- Document ID: US10479836B2
- Status: Granted
- Kind: B2
- Application number: 15/578,864
- Filed: 2016-05-31
- Published: 2018-06-07
- Granted: 2019-11-19
- Earliest claimed: 2015-06-01
- Assignees: National University Corporation University of Toyama; Kyowa Kirin Co., Ltd.
- Applicants: University of Toyama; Kyowa Hakko Kirin Co., Ltd.
- Inventors: Masashi Ikutani; Kiyoshi Takatsu; Hiromi Ehara; Ikuko Fujino; Shinya Ogawa
- Web page: https://patentgrep.com/patent/US10479836B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.

## Claims

### Claim 1

A method for treating pulmonary hypertension, comprising administering an effective amount of an antibody or an antibody fragment thereof which binds to the extracellular region of an interleukin-5 receptor (IL-5R) to inhibit an IL-5R-expressing cell,
wherein said antibody or antibody fragment thereof comprises a heavy chain variable (VH) domain containing 3 complementarity determining regions (CDRs), and a light chain variable (VL) domain containing 3 CDRs,
wherein the 3 CDRs on said VH domain comprise the amino acid sequences of SEQ ID NOs: 1-3, respectively, and the 3 CDRs on said VL domain comprise the amino acid sequences of SEQ ID NOs: 4-6, respectively.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the antibody has antibody-dependent cellular cytotoxic activity (ADCC activity).

### Claim 3 (depends on 1)

The method according to claim 1, wherein the antibody has IL-5R-neutralizing activity.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody inhibits group 2 innate lymphoid cell (ILC2)-dependent IL-5R-expressing cell growth.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the method is characterized by at least one of the following (i) to (iii):
(i) the IL-5R-expressing cell is at least one cell of an eosinophil, a basophil, and a mast cell;
(ii) the method inhibits the growth of a vascular smooth muscle cell; and
(iii) the method inhibits pulmonary vascular remodeling.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antibody is any one antibody selected from a monoclonal antibody and a recombinant antibody.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the antibody comprises a human Fc region or a human constant region.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said VH domain comprises the amino acid sequence of SEQ ID NO: 7, and said VL domain comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 10.